$CRYM
Cryomass Technologies, Inc. Stock $crym

$crym Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000121390024068923 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$5.000K	$13.89K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit	$5.000K	$13.89K
YoY Change
Gross Profit Margin	100.0%	100.0%
Selling, General & Admin		$519.0K	$550.0K
YoY Change		-5.64%	-40.65%
% of Gross Profit		3736.63%
Research & Development			$13.24K
YoY Change			869.82%
% of Gross Profit
Depreciation & Amortization	$13.08K	$13.08K	$13.08K
YoY Change	0.0%	0.0%	-40.1%
% of Gross Profit	261.54%	94.15%
Operating Expenses	$870.9K	$1.111M	$6.275M
YoY Change	-36.59%	-82.3%	343.05%
Operating Profit	-$865.9K	-$1.097M	-$6.275M
YoY Change	-36.95%	-82.52%	343.05%
Interest Expense		-$140.0K	$82.60K
YoY Change		-269.44%	-682.52%
% of Operating Profit
Other Income/Expense, Net	-$236.1K	-$522.9K	-$87.09K
YoY Change	193.03%	500.37%	514.42%
Pretax Income	-$1.102M	-$1.620M	-$6.360M
YoY Change	-24.0%	-74.53%	344.63%
Income Tax
% Of Pretax Income
Net Earnings	-$1.102M	-$1.620M	-$6.362M
YoY Change	-24.21%	-74.54%	344.75%
Net Earnings / Revenue	-22038.66%	-11661.94%
Basic Earnings Per Share	$0.00	-$0.01	-$0.03
Diluted Earnings Per Share	$0.00	-$0.01	-$0.03
COMMON SHARES
Basic Shares Outstanding	235.3M shares	218.7M shares	205.3M shares
Diluted Shares Outstanding	237.0M shares	220.4M shares	205.2M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$497.9K	$316.3K
YoY Change		57.43%	-85.55%
Cash & Equivalents	$183.4K	$497.9K	$316.3K
Short-Term Investments
Other Short-Term Assets		$29.11K	$162.1K
YoY Change		-82.05%	142.58%
Inventory
Prepaid Expenses	$106.6K	$29.11K	$140.4K
Receivables	$6.189K	$6.189K
Other Receivables		$0.00
Total Short-Term Assets	$296.3K	$533.2K	$478.4K
YoY Change	33.38%	11.45%	-78.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$787.8K	$696.9K	$749.2K
YoY Change	7.01%	-6.98%	114.32%
Goodwill	$0.00	$0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$833.4K	$759.6K	$880.3K
YoY Change	-1.98%	-13.71%	-90.99%
TOTAL ASSETS
Total Short-Term Assets	$296.3K	$533.2K	$478.4K
Total Long-Term Assets	$833.4K	$759.6K	$880.3K
Total Assets	$1.130M	$1.293M	$1.359M
YoY Change	5.35%	-4.85%	-88.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$3.329M	$1.591M
YoY Change		109.24%	46.09%
Accrued Expenses
YoY Change
Deferred Revenue	$886.7K	$481.3K
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due		$2.640M	$222.6K
YoY Change		1085.64%
Total Short-Term Liabilities	$7.243M	$6.530M	$1.814M
YoY Change	265.87%	260.04%	66.53%
LONG-TERM LIABILITIES
Long-Term Debt		$565.2K	$2.300M
YoY Change		-75.42%	859.88%
Other Long-Term Liabilities		$2.655M
YoY Change
Total Long-Term Liabilities		$3.220M	$2.300M
YoY Change		40.03%	859.88%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.243M	$6.530M	$1.814M
Total Long-Term Liabilities		$3.220M	$2.300M
Total Liabilities	$10.57M	$9.750M	$4.113M
YoY Change	135.41%	137.04%	209.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$57.24M	-$56.14M	-$46.97M
YoY Change	18.21%	19.52%	46.0%
Common Stock	$237.2K	$235.3K	$205.8K
YoY Change	12.92%	14.34%	2.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.440M	-$8.457M	-$2.755M
YoY Change
Total Liabilities & Shareholders Equity	$1.130M	$1.293M	$1.359M
YoY Change	5.35%	-4.85%	-88.7%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$1.102M	-$1.620M	-$6.362M
YoY Change	-24.21%	-74.54%	344.75%
Depreciation, Depletion And Amortization	$13.08K	$13.08K	$13.08K
YoY Change	0.0%	0.0%	-40.1%
Cash From Operating Activities		-$234.2K	-$999.1K
YoY Change		-76.56%	-25.28%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$35.50K
YoY Change		-100.0%	-126.24%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities		$0.00	-$35.50K
YoY Change		-100.0%	-73.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		708.2K	686.9K
YoY Change		3.09%	938.4%
NET CHANGE
Cash From Operating Activities		-234.2K	-999.1K
Cash From Investing Activities		0.000	-35.50K
Cash From Financing Activities		708.2K	686.9K
Net Change In Cash		474.0K	-347.7K
YoY Change		-236.31%	-75.27%
FREE CASH FLOW
Cash From Operating Activities		-$234.2K	-$999.1K
Capital Expenditures		$0.00	$35.50K
Free Cash Flow		-$234.2K	-$1.035M
YoY Change		-77.37%	-13.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	220446289	shares
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	215196374	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	204881096	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	205232785	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-56155
	dei	Entity Registrant Name EntityRegistrantName	CRYOMASS TECHNOLOGIES INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5051728
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1001 Bannock Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 612
	dei	Entity Address City Or Town EntityAddressCityOrTown	Denver
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80204
	dei	City Area Code CityAreaCode	303
	dei	Local Phone Number LocalPhoneNumber	416-7208
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	235284877	shares
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	497900	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49224	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6189	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8552	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	29108	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	94746	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	533197	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	152522	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	696919	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	723072	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	62708	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	96912	usd
CY2024Q2	us-gaap	Assets Assets	1292824	usd
CY2023Q4	us-gaap	Assets Assets	972506	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3329064	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2236462	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	481250	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	20000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	237500	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6529891	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2493962	usd
CY2024Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	65000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	75000	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	565243	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	597381	usd
CY2024Q2	crym	Contingent Royalty Liability ContingentRoyaltyLiability	2590000	usd
CY2023Q4	crym	Contingent Royalty Liability ContingentRoyaltyLiability	1185000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	9750134	usd
CY2023Q4	us-gaap	Liabilities Liabilities	6821748	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	235284877	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	235284877	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	210032401	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	210032401	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	235286	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	210033	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47448856	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	45907981	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-56141452	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51967256	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-8457310	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-5849242	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1292824	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	972506	usd
CY2024Q2	us-gaap	Revenues Revenues	13889	usd
	us-gaap	Revenues Revenues	19189	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	13889	usd
	us-gaap	Gross Profit GrossProfit	19189	usd
CY2024Q2	crym	Personnel Costs PersonnelCosts	561600	usd
CY2023Q2	crym	Personnel Costs PersonnelCosts	723455	usd
	crym	Personnel Costs PersonnelCosts	1205602	usd
	crym	Personnel Costs PersonnelCosts	1491720	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	254848	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	446149	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	520436	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	786045	usd
CY2024Q2	us-gaap	Legal Fees LegalFees	264135	usd
CY2023Q2	us-gaap	Legal Fees LegalFees	104497	usd
	us-gaap	Legal Fees LegalFees	381139	usd
	us-gaap	Legal Fees LegalFees	403239	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	30179	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	144336	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	60358	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	268865	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13238	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13361	usd
CY2023Q2	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3653043	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3653043	usd
CY2023Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1190000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1190000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	1110762	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	6274718	usd
	us-gaap	Operating Expenses OperatingExpenses	2167535	usd
	us-gaap	Operating Expenses OperatingExpenses	7806273	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1096873	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6274718	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2148346	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7806273	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	149787	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	82602	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	308421	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	136263	usd
CY2024Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	9830	usd
CY2023Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4486	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	26468	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-17796	usd
CY2024Q2	crym	Gain Losson Contingent Royalty Liability GainLossonContingentRoyaltyLiability	-44000	usd
	crym	Gain Losson Contingent Royalty Liability GainLossonContingentRoyaltyLiability	-1405000	usd
CY2024Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-338897	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-338897	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-522854	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-87088	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2025850	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-154059	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1619727	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6361806	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4174196	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7960332	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1619727	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6361806	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4174196	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7960332	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	220446289	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	205232785	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	215196374	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	204881096	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4574468	usd
CY2023Q1	crym	Stock Issued During Period Value Common Stock Issued For Current Period Services StockIssuedDuringPeriodValueCommonStockIssuedForCurrentPeriodServices	65626	usd
CY2023Q1	crym	Stock Issued During Period Value Common Stock Issued For Vested Rs Us For Current Period Services StockIssuedDuringPeriodValueCommonStockIssuedForVestedRSUsForCurrentPeriodServices	50000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	62972	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1598526	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	3154540	usd
CY2023Q2	crym	Stock Issued During Period Value Common Stock Issued For Current Period Services StockIssuedDuringPeriodValueCommonStockIssuedForCurrentPeriodServices	20112	usd
CY2023Q2	crym	Stock Issued During Period Value Common Stock Issued For Vested Rs Us For Current Period Services StockIssuedDuringPeriodValueCommonStockIssuedForVestedRSUsForCurrentPeriodServices	79920	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	173631	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	179026	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6361806	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2754577	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-5849242	usd
CY2024Q1	crym	Adjustment To Additional Capital Stock Options Issued For Current Period Services AdjustmentToAdditionalCapitalStockOptionsIssuedForCurrentPeriodServices	57557	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	28226	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2554469	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-8317928	usd
CY2024Q2	crym	Common Stock And Warrants Issued For Prior Period Services CommonStockAndWarrantsIssuedForPriorPeriodServices	50000	usd
CY2024Q2	crym	Adjustment To Additional Capital Stock Options Issued For Current Period Services AdjustmentToAdditionalCapitalStockOptionsIssuedForCurrentPeriodServices	18915	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	25000	usd
CY2024Q2	crym	Share Issuance From Sale Of Common Stock And Warrants ShareIssuanceFromSaleOfCommonStockAndWarrants	708151	usd
CY2024Q2	crym	Share Issuance From Debt Cancellation ShareIssuanceFromDebtCancellation	678279	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1619727	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-8457310	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4174196	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7960332	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	73752	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	13036	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	60358	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	268865	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	9776	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1413	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1190000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3653043	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-338897	usd
	crym	Gain Losson Contingent Royalty Liability GainLossonContingentRoyaltyLiability	-1405000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	174939	usd
	crym	Common Stock Issued For Vested Rs Us For Current Period Service CommonStockIssuedForVestedRSUsForCurrentPeriodService	129920	usd
	crym	Stockbased Compensation For Vested Rs Us For Current Period Services StockbasedCompensationForVestedRSUsForCurrentPeriodServices	53226	usd
	crym	Stockbased Compensation For Vested Rs Us For Current Period Services StockbasedCompensationForVestedRSUsForCurrentPeriodServices	236603	usd
	crym	Stock Options Issued For Current Period Services StockOptionsIssuedForCurrentPeriodServices	76472	usd
	crym	Adjustment Of Common Stock And Warrants Issued For Prior Period Services AdjustmentOfCommonStockAndWarrantsIssuedForPriorPeriodServices	-50000	usd
	crym	Common Stock Issued For The Current Period Services CommonStockIssuedForTheCurrentPeriodServices	85738	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2363	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-65638	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	11700	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1092602	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	55964	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	531250	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-259475	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2337450	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	49236	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49236	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	686896	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	708151	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	708151	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	686896	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	448676	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1699790	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49224	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2016057	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	497900	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	316267	usd
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	246577	usd
	crym	Debt Discount Recognized From Warrants Issued In Conjunction With Notes Payable DebtDiscountRecognizedFromWarrantsIssuedInConjunctionWithNotesPayable	179026	usd
	crym	Stock Issued For Cancellation Of Debt StockIssuedForCancellationOfDebt	678279	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. Nature of the Business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cryomass Technologies Inc. (the “Company”) develops and licenses cutting-edge equipment and processes to refine harvested cannabis, hemp, and other premium crops. The company’s patented technology harnesses liquid nitrogen to reduce biomass and then efficiently isolate, collect and preserve delicate resin glands (trichomes) containing prized compounds like cannabinoids and terpenes. Building on this technology, Cryomass has engineered its premier Trichome Separation unit (CryoSift Separator™), optimized via patented cryogenic processes to rapidly capture intact, high-value cannabis and hemp trichomes (CryoSift™).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s principal office is located at 1001 Bannock St., Suite 612, Denver, CO 80204, and its telephone number is 303-416-7208. The Company’s website is www.cryomass.com. Information appearing on the website is not incorporated by reference into this report.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cryomass Technologies Inc. is the parent company to wholly-owned subsidiaries Cryomass LLC, Cryomass California LLC, and 1304740 B.C. Unlimited Liability Company dba Cryomass Canada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 22, 2021, the Company entered into an Asset Purchase Agreement with Cryocann USA Corp, a California corporation (“Cryocann”), pursuant to which Company acquired substantially all the assets of Cryocann. The acquired assets included the patented cryogenic process titled “System and method for cryogenic separation of plant material” (US patent #10,864,525) for the reduction of biomass and efficient isolation, collection and preservation of delicate resin glands (trichomes) of harvested of hemp and cannabis, and potentially other high value trichome-rich plants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2021, we were granted an additional patent for our process from the Chinese Intellectual Property Office. In April 2022, we were granted another patent #3,064,896 from the Canadian Intellectual Property Office. We currently are taking steps to gain further protection for our intellectual property through the European Union Intellectual Property Office and other international jurisdictions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The first functional commercial unit, known as a CryoSift Separator™, has been installed at the premises of an operating partner, pursuant to a license and lease arrangement, in California.</span></p>
	crym	Working Deficit WorkingDeficit	5996694	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	497900	usd
	crym	Overhead Costs OverheadCosts	3200000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3125000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-259475	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4174196	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-56141452	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, determining the fair value of the assets acquired and liabilities assumed in acquisition, determining the useful lives and potential impairment of long-lived assets and potential impairment of goodwill. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts. Aside from this, the Company does not believe it is exposed to any unusual credit risk.</span></p>
	crym	Schedule Of Estimated Useful Life Of Property Plant And Equipment ScheduleOfEstimatedUsefulLifeOfPropertyPlantAndEquipment	Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/> Useful Life</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15 years</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	135000	usd
CY2024Q2	crym	Monthly Processing Fee For Equipment Rental Percent MonthlyProcessingFeeForEquipmentRentalPercent	50	g
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.10	pure
	crym	Unexercised Options Shares UnexercisedOptionsShares	19598295	shares
	crym	Unexercised Warrants Outstanding UnexercisedWarrantsOutstanding	80082322	shares
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	696919	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	723072	usd
CY2024Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	777833	usd
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	777833	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	80914	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	54761	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	696919	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	723072	usd
CY2024Q2	us-gaap	Depreciation Depreciation	13077	usd
	us-gaap	Depreciation Depreciation	26153	usd
CY2023Q2	us-gaap	Depreciation Depreciation	13077	usd
	us-gaap	Depreciation Depreciation	23207	usd
CY2024Q2	us-gaap	Goodwill Goodwill	0	usd
CY2023Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1190000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	148219	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	85511	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	62708	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4230482	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	480527	usd
CY2023Q4	crym	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	-3653043	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	96912	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	17102	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	34204	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	131260	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	245659	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	34206	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	28502	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	62708	usd
CY2023Q3	crym	Deferred Revenue Agreement Term DeferredRevenueAgreementTerm	P5Y
	us-gaap	Taxes And Licenses TaxesAndLicenses	100000	usd
CY2023Q3	us-gaap	Taxes And Licenses TaxesAndLicenses	100000	usd
	crym	Territory License Fee Agreement Description TerritoryLicenseFeeAgreementDescription	Territory License Fee, RubberRock had the obligation to pay Cryomass monthly royalties.
	crym	Territory License Fee TerritoryLicenseFee	100000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	65000	usd
	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation	three years with one three-year option to renew
CY2024Q1	us-gaap	Payments For Fees PaymentsForFees	461250	usd
	crym	Subscriptions Agreements Description SubscriptionsAgreementsDescription	The fair value of the Warrants was determined utilizing a Binomial model considering all relevant assumptions at the dates of issuance, including the Company stock price ($0.13 for April subscription agreements, one of which is for Simon Langelier, $0.09 for May subscription agreements, $0.12 for the June subscription agreement, $0.14 for the July subscription agreement, $0.09 for the October subscription agreement, $0.08 for the November subscription agreement), term (4 years), historical volatility (152-154%), and risk-free rate (3.8% for April subscription agreements, 3.6% and 3.7% for May subscription agreements for Mario Gobbo and a private investor, respectively, 4.0% for a June subscription agreement for Health Diplomats Pte Ltd, 4.2% for a July subscription agreement, 5.0% for an October subscription agreement, 4.6% for a November subscription agreement).
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	351054	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	351054	usd
CY2024Q2	us-gaap	Notes Payable NotesPayable	704149	usd
CY2024Q2	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	119625	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	731048	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	731048	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	165805	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	565243	usd
CY2023Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	135000	usd
	crym	Equipment Rental Percentage EquipmentRentalPercentage	0.50	pure
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.10	pure
CY2023Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	187500	shares
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	253552	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	366523	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11513214	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.17
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1962017	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	8085081	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.05
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19598295	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.12
CY2024Q1	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P6Y4M24D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2019574	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19598295	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.12
CY2024Q2	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P6Y1M6D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2038489	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8500000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.18
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1579108	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8500000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.18
CY2023Q1	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P8Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1579108	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8500000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.18
CY2023Q2	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P7Y8M12D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1579108	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	8085081	shares
	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	0.05
	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	634560	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5056800	shares
	crym	Vested Expire Term VestedExpireTerm	2029-01-01
CY2024Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.10	pure
	us-gaap	Royalty Expense RoyaltyExpense	2590000	usd
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2024Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023Q2	crym	Gain Losson Contingent Royalty Liability GainLossonContingentRoyaltyLiability		usd
	crym	Gain Losson Contingent Royalty Liability GainLossonContingentRoyaltyLiability		usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	crym	Stock Issued During Period Value Common Stock Issued For Vested Rs Us For Prior Period Services StockIssuedDuringPeriodValueCommonStockIssuedForVestedRSUsForPriorPeriodServices		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	crym	Gain Losson Contingent Royalty Liability GainLossonContingentRoyaltyLiability		usd
	us-gaap	Paid In Kind Interest PaidInKindInterest		usd
	crym	Common Stock Issued For Vested Rs Us For Current Period Service CommonStockIssuedForVestedRSUsForCurrentPeriodService		usd
	crym	Stock Options Issued For Current Period Services StockOptionsIssuedForCurrentPeriodServices		usd
	crym	Adjustment Of Common Stock And Warrants Issued For Prior Period Services AdjustmentOfCommonStockAndWarrantsIssuedForPriorPeriodServices		usd
	crym	Common Stock Issued For The Current Period Services CommonStockIssuedForTheCurrentPeriodServices		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1		usd
	crym	Debt Discount Recognized From Warrants Issued In Conjunction With Notes Payable DebtDiscountRecognizedFromWarrantsIssuedInConjunctionWithNotesPayable		usd
	crym	Stock Issued For Cancellation Of Debt StockIssuedForCancellationOfDebt		usd
CY2024Q2	crym	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment		usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear		usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo		usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree		usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q1	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeited
CY2024Q1	crym	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeiture In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodTotalIntrinsicValue		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q2	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeited
CY2024Q2	crym	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeiture In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodTotalIntrinsicValue		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2023Q1	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Aggregate Intrinsic Value Granted And Vested SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAggregateIntrinsicValueGrantedAndVested		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q1	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeited
CY2023Q1	crym	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeiture In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodTotalIntrinsicValue		usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2023Q2	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Aggregate Intrinsic Value Granted And Vested SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAggregateIntrinsicValueGrantedAndVested		usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q2	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeited
CY2023Q2	crym	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeiture In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodTotalIntrinsicValue		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001533030
	dei	No Trading Symbol Flag NoTradingSymbolFlag	true
	dei	Security Exchange Name SecurityExchangeName	NONE
	dei	Security12b Title Security12bTitle	None

Files In Submission

Name	View Source	Status
0001213900-24-068923-index-headers.html	Edgar Link	pending
0001213900-24-068923-index.html	Edgar Link	pending
0001213900-24-068923.txt	Edgar Link	pending
0001213900-24-068923-xbrl.zip	Edgar Link	pending
crym-20240630.xsd	Edgar Link	pending
ea0211008-10q_cryomass.htm	Edgar Link	pending
ea021100801ex31-1_cryomass.htm	Edgar Link	pending
ea021100801ex31-2_cryomass.htm	Edgar Link	pending
ea021100801ex32-1_cryomass.htm	Edgar Link	pending
ea021100801ex32-2_cryomass.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
crym-20240630_lab.xml	Edgar Link	unprocessable
crym-20240630_pre.xml	Edgar Link	unprocessable
ea0211008-10q_cryomass_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
crym-20240630_cal.xml	Edgar Link	unprocessable
crym-20240630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRYM
Cryomass Technologies, Inc. Stock $crym

2024 Q3 Form 10-Q Financial Statement

#000121390024068923 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRYM Cryomass Technologies, Inc. Stock $crym

2024 Q3 Form 10-Q Financial Statement

#000121390024068923 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRYM
Cryomass Technologies, Inc. Stock $crym